Friday, July 10, 2026

Drug profile · INN

ioflupane i-123

ioflupane i-123 (IOFLUPANE I-123) is a diagnostic agent. Route of administration: intravenous. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — ioflupane i-123
US status
approved
Class
Route
INTRAVENOUS
Patents
0
Programs
2
Data quality
0.84

Quick answer

ioflupane i-123 (IOFLUPANE I-123) is a diagnostic agent. Route of administration: intravenous. Current US regulatory status: approved.

Key facts

INN ioflupane i-123
Brand IOFLUPANE I-123
Mechanism Diagnostic agent
Route INTRAVENOUS
Formulation SOLUTION

Mechanism of action

Diagnostic agent

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. BHV8000-301 Phase 3 · Biohaven Bioscience Ireland · Early Parkinson’s Disease
  2. SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM Phase 3 · Ars Pharmaceuticals Irl · Amyotrophic Lateral Sclerosis

Frequently asked questions

What is ioflupane i-123?

ioflupane i-123 (IOFLUPANE I-123) is a diagnostic agent. Route of administration: intravenous. Current US regulatory status: approved.

What is the brand name for ioflupane i-123?

IOFLUPANE I-123 is a marketed brand name for ioflupane i-123. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of ioflupane i-123?

ioflupane i-123 has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.